PHD Chamber of Commerce and Industry hosted a webinar on "Cancer Care during COVID Times: Tackling of NCDs" with august panelist from the medical fraternity including Dr. N Subramanian, Chairman, Health Committee, PHD Chamber and Director, Medical Services, Indraprastha Apollo Hospitals; Dr. Gopi Chand Khilnani, Chairman, Pulmonary, Critical Care and Sleep Medicine, PSRI Hospital; Dr. Amish Vora, Co-Founder, and Director, Medical Oncology, H.O.P.E. Oncology Clinic & Sr.
A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent.
Caption : A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer. Credit : Hayley Schultz/UniSA